CD274 and cancer: Gefitinib, an EGFR inhibitor that is used as a treatment in many cancers, also inhibits PD-L1 glycosylation and in turn promotes GSK3β-mediated ubiquitination and degradation, which results in the enhancement of efficacy of anti-PD-1 therapy.34 (2) Targeting checkpoint ubiquitination/degradation.